Soumit Roy
Stock Analyst at Jones Trading
(2.95)
# 1,556
Out of 5,182 analysts
46
Total ratings
34.29%
Success rate
15.07%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Soumit Roy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EDIT Editas Medicine | Upgrades: Buy | $8 | $2.89 | +176.82% | 2 | Mar 10, 2026 | |
| DAWN Day One Biopharmaceuticals | Downgrades: Hold | $20 → $22 | $21.48 | +0.09% | 1 | Mar 6, 2026 | |
| WHWK Whitehawk Therapeutics | Initiates: Buy | $7 | $3.55 | +97.18% | 1 | Dec 22, 2025 | |
| CNTX Context Therapeutics | Initiates: Buy | $7 | $2.59 | +170.27% | 1 | Dec 22, 2025 | |
| EVAX Evaxion | Initiates: Buy | $10 | $4.11 | +143.31% | 1 | Oct 30, 2025 | |
| AVXL Anavex Life Sciences | Downgrades: Hold | n/a | $3.05 | - | 1 | Oct 24, 2025 | |
| ATYR aTyr Pharma | Downgrades: Hold | n/a | $0.75 | - | 2 | Sep 15, 2025 | |
| CGON CG Oncology | Initiates: Buy | $50 | $68.56 | -27.07% | 1 | Sep 8, 2025 | |
| TARA Protara Therapeutics | Initiates: Buy | $21 | $5.31 | +295.48% | 1 | May 22, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $40 | $27.25 | +46.79% | 1 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $27 | $45.59 | -40.78% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.55 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.04 | - | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $4.03 | +272.21% | 3 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.63 | +115.98% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $34 | $26.33 | +29.13% | 2 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $1.43 | +2,417.48% | 4 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $4.28 | +647.66% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $10.29 | -12.54% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $17 | $10.38 | +63.78% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $96 → $64 | $6.86 | +832.94% | 2 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $4.51 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $26 | $15.21 | +70.94% | 2 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $14.53 | +381.76% | 1 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $10 | $57.92 | -82.73% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $2.34 | - | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $80 | $12.62 | +533.91% | 1 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.69 | - | 2 | Nov 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $320 | $0.34 | +94,771.03% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $810 | $6.61 | +12,154.16% | 1 | Feb 24, 2021 |
Editas Medicine
Mar 10, 2026
Upgrades: Buy
Price Target: $8
Current: $2.89
Upside: +176.82%
Day One Biopharmaceuticals
Mar 6, 2026
Downgrades: Hold
Price Target: $20 → $22
Current: $21.48
Upside: +0.09%
Whitehawk Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $3.55
Upside: +97.18%
Context Therapeutics
Dec 22, 2025
Initiates: Buy
Price Target: $7
Current: $2.59
Upside: +170.27%
Evaxion
Oct 30, 2025
Initiates: Buy
Price Target: $10
Current: $4.11
Upside: +143.31%
Anavex Life Sciences
Oct 24, 2025
Downgrades: Hold
Price Target: n/a
Current: $3.05
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.75
Upside: -
CG Oncology
Sep 8, 2025
Initiates: Buy
Price Target: $50
Current: $68.56
Upside: -27.07%
Protara Therapeutics
May 22, 2025
Initiates: Buy
Price Target: $21
Current: $5.31
Upside: +295.48%
ArriVent BioPharma
May 20, 2025
Initiates: Buy
Price Target: $40
Current: $27.25
Upside: +46.79%
May 16, 2025
Maintains: Buy
Price Target: $36 → $27
Current: $45.59
Upside: -40.78%
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.55
Upside: -
May 16, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.04
Upside: -
Mar 13, 2025
Upgrades: Buy
Price Target: $15
Current: $4.03
Upside: +272.21%
Mar 12, 2025
Initiates: Buy
Price Target: $10
Current: $4.63
Upside: +115.98%
Mar 10, 2025
Upgrades: Buy
Price Target: $34
Current: $26.33
Upside: +29.13%
Feb 11, 2025
Upgrades: Buy
Price Target: $36
Current: $1.43
Upside: +2,417.48%
Jan 28, 2025
Initiates: Buy
Price Target: $32
Current: $4.28
Upside: +647.66%
Oct 31, 2024
Initiates: Buy
Price Target: $9
Current: $10.29
Upside: -12.54%
Oct 31, 2024
Initiates: Buy
Price Target: $17
Current: $10.38
Upside: +63.78%
Sep 11, 2024
Maintains: Buy
Price Target: $96 → $64
Current: $6.86
Upside: +832.94%
May 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $4.51
Upside: -
Apr 17, 2024
Maintains: Buy
Price Target: $22 → $26
Current: $15.21
Upside: +70.94%
Apr 16, 2024
Initiates: Buy
Price Target: $70
Current: $14.53
Upside: +381.76%
Apr 11, 2024
Upgrades: Buy
Price Target: $10
Current: $57.92
Upside: -82.73%
May 23, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.34
Upside: -
Apr 19, 2023
Initiates: Buy
Price Target: $80
Current: $12.62
Upside: +533.91%
Nov 16, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.69
Upside: -
Nov 8, 2022
Initiates: Buy
Price Target: $320
Current: $0.34
Upside: +94,771.03%
Feb 24, 2021
Initiates: Buy
Price Target: $810
Current: $6.61
Upside: +12,154.16%